HOME > COLUMN
COLUMN
-
The Impact of a Shrinking Labor Market on the Healthcare Industry
June 23, 2023
-
Seven Recruitment Trends in 2023
May 31, 2023
-
The Inflation Reduction Act - Implications for Japanese Pharmaceutical Manufacturers
May 19, 2023
-
How to Serve and Get Ahead
April 21, 2023
-
The Increasing Impact of Real-World Evidence
March 31, 2023
-
Rewarding Value and Innovation and Ensuring Financial Viability of the Biopharmaceutical Supply Chain in Japan
March 16, 2023
-
Why Market Mapping Is Critical to Your Organization
February 24, 2023
-
When It Comes to Recruitment, Time Is Money. Have a Plan!
January 31, 2023
-
Cell Therapy in Japan: A Potentially Attractive Market at a Turning Point Facing Challenges
December 16, 2022
-
How to Succeed in Bad Times and Good
December 9, 2022
-
The Pros and Cons of Working from Home in 2022
November 25, 2022
-
Rare Diseases in Japan: Moving from Treatment to Integrated Care
October 27, 2022
-
The Evolving US Managed Care Environment and Implications of US Market Attractiveness for Japanese Manufacturers
September 5, 2022
-
Fairness, Not Diversity
August 26, 2022
-
Healthcare Collaboration between Governments and Biopharma: Key Success Factors for Life Science Manufacturers and Future Implications
August 5, 2022
-
The Winning Combination: Drive, Passion, and Commitment
July 22, 2022
-
Please Come Back to the Office!
June 24, 2022
-
Customer Engagement in the COVID-Endemic New Normal
June 17, 2022
-
Tapping into One’s Ikigai by Working from Home
May 27, 2022
-
The Road to Success Is Paved with the Stepping-Stones of Disappointment
April 22, 2022
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
